Somewhat Favorable Media Coverage Somewhat Unlikely to Impact Impax Laboratories (IPXL) Stock Price
Headlines about Impax Laboratories (NASDAQ:IPXL) have trended somewhat positive this week, Accern Sentiment Analysis reports. The research group ranks the sentiment of news coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Impax Laboratories earned a media sentiment score of 0.19 on Accern’s scale. Accern also gave media headlines about the specialty pharmaceutical company an impact score of 46.7015455566811 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
A number of brokerages recently issued reports on IPXL. Cowen Inc reiterated a “hold” rating and issued a $16.00 target price on shares of Impax Laboratories in a report on Friday, November 10th. Cantor Fitzgerald increased their target price on Impax Laboratories from $25.00 to $35.00 and gave the stock an “overweight” rating in a report on Friday, November 10th. UBS AG increased their target price on Impax Laboratories from $12.00 to $16.00 and gave the stock a “sell” rating in a report on Monday, October 30th. Zacks Investment Research cut Impax Laboratories from a “hold” rating to a “sell” rating in a report on Friday, October 20th. Finally, Royal Bank Of Canada set a $17.00 target price on Impax Laboratories and gave the stock a “hold” rating in a report on Tuesday, October 17th. Three investment analysts have rated the stock with a sell rating, nine have issued a hold rating and five have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus target price of $19.60.
Impax Laboratories (NASDAQ:IPXL) opened at $17.05 on Monday. The company has a debt-to-equity ratio of 1.59, a quick ratio of 1.32 and a current ratio of 1.81. Impax Laboratories has a 52 week low of $7.75 and a 52 week high of $25.70. The firm has a market capitalization of $1,263.64, a price-to-earnings ratio of 25.07, a price-to-earnings-growth ratio of 1.08 and a beta of 0.99.
Impax Laboratories (NASDAQ:IPXL) last issued its quarterly earnings data on Thursday, November 9th. The specialty pharmaceutical company reported $0.23 earnings per share for the quarter, beating the consensus estimate of $0.20 by $0.03. Impax Laboratories had a positive return on equity of 9.06% and a negative net margin of 56.59%. The business had revenue of $206.40 million for the quarter, compared to analysts’ expectations of $208.38 million. During the same period last year, the business earned $0.37 EPS. The business’s revenue was down 9.4% on a year-over-year basis. equities research analysts anticipate that Impax Laboratories will post 0.63 earnings per share for the current year.
ILLEGAL ACTIVITY NOTICE: “Somewhat Favorable Media Coverage Somewhat Unlikely to Impact Impax Laboratories (IPXL) Stock Price” was published by Watch List News and is owned by of Watch List News. If you are reading this story on another domain, it was copied illegally and republished in violation of United States & international trademark & copyright legislation. The legal version of this story can be accessed at https://www.watchlistnews.com/somewhat-favorable-media-coverage-somewhat-unlikely-to-impact-impax-laboratories-ipxl-stock-price/1728450.html.
About Impax Laboratories
Impax Laboratories, Inc is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), in addition to the development and marketing of branded products. Its segments include Impax Generics and Impax Specialty Pharma.
Receive News & Ratings for Impax Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Impax Laboratories Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.